On April 1, 2021, Richards, Nicole; Lewis, Richard; Hamilton, Matthew; Ray, William; Alvarez, Fernando; Pfaffinger, Dana; Reyna, Naphtali; Cross, Jason; Ramaswamy, Suyambu Kesava Vijayan; Bardenhagen, Jennifer; Lightfoot, Yaima Luzardo; Acton, Paul; Goodwani, Sunil published a patent.Reference of 5-Methoxy-1H-pyrazole The title of the patent was Preparation of 1-[(4,5-dihydro-1H-pyrazol-1-yl)carbonyl]bicyclo[1.1.1]pentane derivatives as inhibitors of receptor interacting protein kinase for the treatment of disease. And the patent contained the following:
The is invention is related to the preparation of compounds I [X = a bond, carbamoyl, carbonyl, (un)substituted alkylene; R1a, R1b = independently H, (un)substituted alkyl; or R1aNR1b= (un)substituted heterocycloalkyl or heteroaryl; R2 = H, OH, CN, halo, NH2, etc.] or salts thereof which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer. Thus, Wittig reaction between 3,5-difluorobenzaldehyde and 2-(triphenylphosphoranylidene)acetaldehyde, cyclization of (E)-3-(3,5-difluorophenyl)-2-propenal with NH2NH2 and reaction of 5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole with 3-(methoxycarbonyl)bicyclo[1.1.1]pentane-1-carboxylic acid gave II. Exemplified compounds I were tested for their RIPK1 activity (data given for representative compounds I). The experimental process involved the reaction of 5-Methoxy-1H-pyrazole(cas: 215610-30-3).Reference of 5-Methoxy-1H-pyrazole
The Article related to dihydropyrazolylcarbonylbicyclopentane derivative preparation receptor interacting protein kinase 1 inhibitor, ripk1 inhibitor dihydropyrazolylcarbonylbicyclopentane derivative preparation antiinflammatory anticancer neurodegenerative disorder and other aspects.Reference of 5-Methoxy-1H-pyrazole
Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics